People · Operator
Named in public records as an officer, director or promoter · active 2011–2012 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nitric BioTherapeutics, Inc. | — | Biotechnology | Seed | $5.5M | $45.3M | 2011 |
James J. Ratigan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James J. Ratigan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Zev Scherl | 1 | 3 |
| Matthew Rieke | 1 | 3 |
| Brian M Gallagher | 1 | 3 |
| Richard Caruso | 1 | 2 |
| Al M. Altomari | 1 | 2 |
| Matthew M. Rieke | 1 | 1 |
| Marcus J. Schabacker | 1 | 1 |
| Harold Chefitz | 1 | 1 |
| Hugh MacNaught | 1 | 1 |
| Frank J. McCaney | 1 | 1 |
| Adele M. Oliva | 1 | 1 |
| Jeffrey M. O'Donnell | 1 | 1 |
| Zev M. Scherl | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.